-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Once Again Ranked Among the Top 50 Chinese Chemical Pharmaceutical R&D Companies
Category:
发布时间：2021-09-23
【概要描述】
On September 18, at the 2021 High-Quality Development Conference for the Greater Health Industry and the 6th China Pharmaceutical R&D and Innovation Summit (PDI) held in Chongqing, the 2021 Top 100 Ranking of Chinese Chemical Pharmaceutical R&D Strength was unveiled. Shijiazhuang Sihua Pharmaceutical Co., Ltd. ranked 44th, once again securing a place among the top 50 Chinese chemical pharmaceutical R&D companies.
On September 18, at the 2021 High-Quality Development Conference for the Greater Health Industry and the 6th China Pharmaceutical R&D and Innovation Summit (PDI) held in Chongqing, the 2021 Top 100 Ranking of China’s Chemical Pharmaceutical R&D Strength was unveiled. Shijiazhuang Sihua Pharmaceutical Co., Ltd. ranked 44th, once again securing a place among the top 50 Chinese chemical pharmaceutical R&D companies.
R&D investment is a key indicator of innovation capability. According to data from Frost & Sullivan, R&D spending by innovative pharmaceutical companies has grown steadily over the past five years: from US$11.9 billion in 2016 to US$27.0 billion in 2020, representing a compound annual growth rate of 22.7%. Among the companies on the list, 24 reported R&D expenditures exceeding RMB 500 million in 2020, with 8 surpassing RMB 1 billion.
With the implementation of policies such as the “Generic Drug Consistency Evaluation,” “Volume-Based Procurement,” “Medical Insurance Negotiation,” and the “MAH System,” the market landscape of the pharmaceutical industry is undergoing continuous adjustment and differentiation. The competitive dynamics are shifting from a production-centric model to one centered on R&D capabilities and drug innovation, thereby presenting unprecedented development opportunities for innovation-driven, R&D-focused enterprises.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091